Drug Discovery & Development
At SLAS 2023, companies showcase, launch advanced automation and screening technologies
At the Society for Laboratory Automation and Screening (SLAS) 2023 International Conference and Exhibition, being held in San Diego from February 25 to March 1, numerous firms have announced that they are showcasing emerging technologies for advanced life science applications. Read More
Agilent launches cell analysis workflow automation for immuno-oncology, virology, and vaccine development
Agilent Technologies on Friday announced that it has integrated its xCelligence RTCA HT (real-time cell analysis high-throughput) platform with the firm’s BioTek BioSpa 8 Automated Incubator, enabling a higher level of workflow automation. Read More
Survey finds physicians are comfortable prescribing Humira biosimilars if treatments are interchangeable
Most specialist physicians would be comfortable prescribing biosimilar versions of adalimumab (Humira), giving a boost to the companies seeking to capitalize on its loss of exclusivity. Read More
Meta-analysis reveals which antibody appears best at preventing RSV infection
A meta-analysis has found an investigational antibody is as effective at preventing respiratory syncytial virus (RSV) infection and associated negative health outcomes as the incumbent product. Read More
Multidrug-resistant bacteria cooperate to reduce the impact of antibiotics: study
Two of the most dangerous multidrug-resistant pathogens work together to nullify antibiotics, suggesting physicians need to determine if both bacteria are present before selecting a treatment regimen. Read More
Atomic AI closes $35M Series A financing
Biotech firm Atomic AI recently announced it the closing of a $35 million Series A round led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, GitHub’s ex-CEO Nat Friedman, Doug Mohr, Curai CEO Neal Khosla, and UC Berkeley Professor and Arc Institute co-founder Patrick Hsu. Read More
Mixing cancer drugs in nanoparticle combinations improves efficacy in mice
Using polymer nanoparticles to carry multiple cancer drugs achieves better outcomes than administering the combination of therapeutics without a delivery vehicle, according to preclinical research published on 26 January in Nature Nanotechnology. Read More
'Living medicine' for drug-resistant lung infections
Researchers have engineered a bacterium that serves as a “living medicine” to treat antibiotic-resistant lung infections -- the leading cause of hospital mortality. The research, published January 19 in the journal Nature Biotechnology and supported through CaixaResearch Health, focused on the antibiotic-resistant bacterium Pseudomonas aeruginosa, a common source of difficult-to-treat hospital infections. Read More
Machine learning models predict release profile to accelerate drug development
Machine learning models have predicted the drug release profiles of long-acting injectable medicines, suggesting that the algorithms can accelerate the development of a promising class of therapies. Read More
Wyss Institute launches RNA therapeutics startup EnPlusOne Biosciences
Wyss Institute at Harvard University has partnered with Northpond Labs to launch EnPlusOne Biosciences. The startup aims to bring versatile, scalable RNA synthesis technology to market, with the goal of unlocking the development of new RNA drugs, vaccines, and gene-editing therapies. Read More
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter